Literature DB >> 7468946

Inhalation of racemic epinephrine in children with asthma. Dose-response relation and comparison with salbutamol.

B Kjellman, H Tollig, G Wettrell.   

Abstract

In this study the effects of nebulized racemic epinephrine (Micronephrine) were investigated in children with asthma. The drug was inhaled by a compressor nebulizer with a plastic mask. In the first part of the study it is shown that nebulized Micronephrine has a dose-dependent bronchodilatory effect. In the second part the effect is compared with that of nebulized salbutamol in 10 children (7-16 years of age) with bronchial asthma. The highest dose used in the dose-response trials (=0.9 mg Micronephrine/kg body-weight) was compared with 0.15 mg salbutamol/kg body-weight, which is the dose commonly used in Sweden. There was no significant difference between the drugs as regards increase of forced expiratory volume in 1 sec or duration of the increase. There was a small but significant increase in systolic blood pressure, measured 5 min after the inhalation of Micronephrine but no significant change in diastolic pressure or heart rate. Four children complained of temporary sore throat after the inhalation.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 7468946     DOI: 10.1111/j.1398-9995.1980.tb01811.x

Source DB:  PubMed          Journal:  Allergy        ISSN: 0105-4538            Impact factor:   13.146


  3 in total

1.  Nebulised racemic adrenaline in the treatment of acute bronchiolitis in infants and toddlers.

Authors:  S Kristjánsson; K C Lødrup Carlsen; G Wennergren; I L Strannegård; K H Carlsen
Journal:  Arch Dis Child       Date:  1993-12       Impact factor: 3.791

2.  Comparison of the effects of salbutamol and adrenaline on airway smooth muscle contractility in vitro and on bronchial reactivity in vivo.

Authors:  D R Baldwin; Z Sivardeen; I D Pavord; A J Knox
Journal:  Thorax       Date:  1994-11       Impact factor: 9.139

Review 3.  Emergency presentation and management of acute severe asthma in children.

Authors:  Knut Øymar; Thomas Halvorsen
Journal:  Scand J Trauma Resusc Emerg Med       Date:  2009-09-04       Impact factor: 2.953

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.